Junichi Kushioka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junichi Kushioka has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Hideki Yoshikawa
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
11 shared publications- Takashi Kaito
Department of Orthopedic Surgery, Osaka Rosai Hospital, Osaka, Japan
9 shared publications - Takahiro Makino
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
7 shared publications Yusuke Sakai
Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan
7 shared publicationsShota Takenaka
Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan
6 shared publications- Stuart Barry Goodman
Stanford University Medical Center
6 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (11) , 1236
CCL2 Facilitates Osteoclastogenesis and Osteogenesis in Both Young and Aged Female Murine MSC–Macrophage Co-Cultures
“Inflammaging” is the presence of continuous systemic low-level chronic inflammation with increasing age, and impairs bone healing. C-C motif chemokine ligand 2 (CCL2) promotes the migration of macrophages during acute inflammation, and subsequent macrophage–mesenchymal stromal cell (MSC) crosstalk. We hypothesized that CCL2 would enhance bone regeneration in both young and aged primary murine cells and investigated the effects of CCL2 on osteogenesis and osteoclastogenesis. In the following experiments, 10–12-week-old and 15–17-month-old female mice were used. For the osteogenic differentiation, MSCs and naïve uncommitted macrophages (M0) were isolated and co-cultured to investigate the effect of CCL2 on the cell–cell interaction, alkaline phosphatase (ALP), and Alizarin-Red staining. For the osteoclastogenic differentiation, primary bone marrow cells were isolated and cultured, then TRAP and Cathepsin K staining and quantitative real-time RT-PCR were performed. In the CCL2-treated group, cells were cultured with recombinant CCL2 for an initial 24 h. MSCs from young mice showed greater osteogenic ability than aged mice. The CCL2-treated group showed a greater Alizarin-Red-positive area both in young and aged cells. In the osteoclastogenic differentiation assays, the number of tartrate-resistant acid phosphatase (TRAP)-positive cells and the expression level of C-fos and Dc-stamp were increased in the CCL2-treated group both in young and aged cells. These findings indicate that CCL2 promotes osteogenesis, particularly mineralization, and enhances selected osteoclastogenic features in both young and aged primary murine cells. These effects suggest that CCL2 may have a potential role in bone remodeling, including in the context of aging.
- 22 October 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (11) , 1236
Open AccessCCL2 Facilitates Osteoclastogenesis and Osteogenesis in Both Young and Aged Female Murine MSC–Macrophage Co-Cultures
“Inflammaging” is the presence of continuous systemic low-level chronic inflammation with increasing age, and impairs bone healing. C-C motif chemokine ligand 2 (CCL2) promotes the migration of macrophages during acute inflammation, and subsequent macrophage–mesenchymal stromal cell (MSC) crosstalk. We hypothesized that CCL2 would enhance bone regeneration in both young and aged primary murine cells and investigated the effects of CCL2 on osteogenesis and osteoclastogenesis. In the following experiments, 10–12-week-old and 15–17-month-old female mice were used. For the osteogenic differentiation, MSCs and naïve uncommitted macrophages (M0) were isolated and co-cultured to investigate the effect of CCL2 on the cell–cell interaction, alkaline phosphatase (ALP), and Alizarin-Red staining. For the osteoclastogenic differentiation, primary bone marrow cells were isolated and cultured, then TRAP and Cathepsin K staining and quantitative real-time RT-PCR were performed. In the CCL2-treated group, cells were cultured with recombinant CCL2 for an initial 24 h. MSCs from young mice showed greater osteogenic ability than aged mice. The CCL2-treated group showed a greater Alizarin-Red-positive area both in young and aged cells. In the osteoclastogenic differentiation assays, the number of tartrate-resistant acid phosphatase (TRAP)-positive cells and the expression level of C-fos and Dc-stamp were increased in the CCL2-treated group both in young and aged cells. These findings indicate that CCL2 promotes osteogenesis, particularly mineralization, and enhances selected osteoclastogenic features in both young and aged primary murine cells. These effects suggest that CCL2 may have a potential role in bone remodeling, including in the context of aging.
- Open Access
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (6) , e0001530
A single-camera video-based assessment of locomotive syndrome using pose-silhouette fusion model
Locomotive syndrome (LS), characterized by declining mobility due to musculoskeletal disorders, significantly affects older adults and is highly prevalent in Japan. Early detection and intervention are crucial to mitigate disease progression and preserve quality of life. Current diagnostic methods rely on subjective self-reports and labor-intensive clinical assessments, underscoring the need for automated, objective, and scalable screening tools. Building on our previous work, this study presents an updated deep learning-based computer vision model for LS screening using single-camera walking videos. We collected 511 walking videos from 178 participants clinically classified into four LS stages (non-LS, stage 1, stage 2, and stage 3). We used the MMPose framework to extract 2D body keypoints and generated silhouette-based Gait Energy Images (GEIs) from seven frames automatically sampled from fixed 40-frame walking windows to capture complementary gait-shape information. Model performance was evaluated using 10-fold cross-validation based on held-out evaluation-window predictions, while ensuring that windows from the same participant and the same walking video were not split across training, validation, and test sets. We also evaluated an independent external validation cohort of 33 cases (LS0–1, n = 15; LS2–3, n = 18). In internal validation, the pose-estimation model achieved sensitivity of 0.9440 and an AUC of 0.9668, whereas the silhouette model showed specificity of 0.9085 and an AUC of 0.9191. Fusion models outperformed the individual approaches, with the highest F1-score (0.908) at a 60:40 pose-to-silhouette ratio and the highest AUC (0.971) at a 70:30 ratio. In external validation, the score-fusion model achieved 90.9% accuracy, 88.9% sensitivity, 93.3% specificity, a macro-F1 score of 0.909, and an AUC of 0.967. In conclusion, integrating pose-estimation and silhouette-based features substantially improves the accuracy and clinical utility of automated LS screening. This low-burden approach provides a practical bridge between population-level screening and definitive clinical assessment.
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (6) , e0001530
Open AccessA single-camera video-based assessment of locomotive syndrome using pose-silhouette fusion model
Locomotive syndrome (LS), characterized by declining mobility due to musculoskeletal disorders, significantly affects older adults and is highly prevalent in Japan. Early detection and intervention are crucial to mitigate disease progression and preserve quality of life. Current diagnostic methods rely on subjective self-reports and labor-intensive clinical assessments, underscoring the need for automated, objective, and scalable screening tools. Building on our previous work, this study presents an updated deep learning-based computer vision model for LS screening using single-camera walking videos. We collected 511 walking videos from 178 participants clinically classified into four LS stages (non-LS, stage 1, stage 2, and stage 3). We used the MMPose framework to extract 2D body keypoints and generated silhouette-based Gait Energy Images (GEIs) from seven frames automatically sampled from fixed 40-frame walking windows to capture complementary gait-shape information. Model performance was evaluated using 10-fold cross-validation based on held-out evaluation-window predictions, while ensuring that windows from the same participant and the same walking video were not split across training, validation, and test sets. We also evaluated an independent external validation cohort of 33 cases (LS0–1, n = 15; LS2–3, n = 18). In internal validation, the pose-estimation model achieved sensitivity of 0.9440 and an AUC of 0.9668, whereas the silhouette model showed specificity of 0.9085 and an AUC of 0.9191. Fusion models outperformed the individual approaches, with the highest F1-score (0.908) at a 60:40 pose-to-silhouette ratio and the highest AUC (0.971) at a 70:30 ratio. In external validation, the score-fusion model achieved 90.9% accuracy, 88.9% sensitivity, 93.3% specificity, a macro-F1 score of 0.909, and an AUC of 0.967. In conclusion, integrating pose-estimation and silhouette-based features substantially improves the accuracy and clinical utility of automated LS screening. This low-burden approach provides a practical bridge between population-level screening and definitive clinical assessment.
- Open Access
Temporal Patterns of Wearable Accelerometer-Measured Physical Activity and Symptom Worsening in Knee Osteoarthritis: A 2-Year Longitudinal Study from the Osteoarthritis Initiative
This study investigates the link between changes in physical activity (PA) measured by wearable accelerometers and the worsening of knee osteoarthritis (KOA) symptoms over two years. Using data from 782 participants in the Osteoarthritis Initiative accelerometer sub-study, PA was tracked with hip-worn ActiGraphs. Participants were classified as “worsening” if their Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score increased by >10 points and as “stable” otherwise. PA was categorized into daily counts and minutes spent in various intensity levels, and analyzed in 3 h intervals across the day. Of the participants, 123 (15.7%) experienced worsening symptoms. At baseline, both groups had similar characteristics aside from slower sit-to-stand times in the worsening group. Over two years, the worsening group had a greater decline in total daily activity counts (−18% vs. −10%) and more significant reductions during late afternoon and evening (15:00–21:00; −21% vs. −6%). This group also showed a notable decrease in gait speed, longer sit-to-stand times, and a trend towards greater medial joint space narrowing. These findings suggest that larger declines in PA, especially in activities in the late afternoon and evening, are associated with worsening KOA symptoms, although causality cannot be established.
Open AccessTemporal Patterns of Wearable Accelerometer-Measured Physical Activity and Symptom Worsening in Knee Osteoarthritis: A 2-Year Longitudinal Study from the Osteoarthritis Initiative
This study investigates the link between changes in physical activity (PA) measured by wearable accelerometers and the worsening of knee osteoarthritis (KOA) symptoms over two years. Using data from 782 participants in the Osteoarthritis Initiative accelerometer sub-study, PA was tracked with hip-worn ActiGraphs. Participants were classified as “worsening” if their Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score increased by >10 points and as “stable” otherwise. PA was categorized into daily counts and minutes spent in various intensity levels, and analyzed in 3 h intervals across the day. Of the participants, 123 (15.7%) experienced worsening symptoms. At baseline, both groups had similar characteristics aside from slower sit-to-stand times in the worsening group. Over two years, the worsening group had a greater decline in total daily activity counts (−18% vs. −10%) and more significant reductions during late afternoon and evening (15:00–21:00; −21% vs. −6%). This group also showed a notable decrease in gait speed, longer sit-to-stand times, and a trend towards greater medial joint space narrowing. These findings suggest that larger declines in PA, especially in activities in the late afternoon and evening, are associated with worsening KOA symptoms, although causality cannot be established.
- Open Access
- 26 November 2024
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 3 (11) , e0000668
Deep learning-based screening for locomotive syndrome using single-camera walking video: Development and validation study
Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. Early diagnosis is vital as LS can be reversed with appropriate intervention. Although diagnosing LS using standardized charts is straightforward, the labor-intensive and time-consuming nature of the process limits its widespread implementation. To address this, we introduced a Deep Learning (DL)-based computer vision model that employs OpenPose for pose estimation and MS-G3D for spatial-temporal graph analysis. This model objectively assesses gait patterns through single-camera video captures, offering a novel and efficient method for LS prediction and analysis. Our model was trained and validated using a dataset of 186 walking videos, plus 65 additional videos for external validation. The model achieved an average sensitivity of 0.86, demonstrating high effectiveness in identifying individuals with LS. The model’s positive predictive value was 0.85, affirming its reliable LS detection, and it reached an overall accuracy rate of 0.77. External validation using an independent dataset confirmed strong generalizability with an Area Under the Curve of 0.75. Although the model accurately diagnosed LS cases, it was less precise in identifying non-LS cases. This study pioneers in diagnosing LS using computer vision technology for pose estimation. Our accessible, non-invasive model serves as a tool that can accurately diagnose the labor-intensive LS tests using only visual assessments, streamlining LS detection and expediting treatment initiation. This significantly improves patient outcomes and marks a crucial advancement in digital health, addressing key challenges in management and care of LS.
- 26 November 2024
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 3 (11) , e0000668
Open AccessDeep learning-based screening for locomotive syndrome using single-camera walking video: Development and validation study
Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. Early diagnosis is vital as LS can be reversed with appropriate intervention. Although diagnosing LS using standardized charts is straightforward, the labor-intensive and time-consuming nature of the process limits its widespread implementation. To address this, we introduced a Deep Learning (DL)-based computer vision model that employs OpenPose for pose estimation and MS-G3D for spatial-temporal graph analysis. This model objectively assesses gait patterns through single-camera video captures, offering a novel and efficient method for LS prediction and analysis. Our model was trained and validated using a dataset of 186 walking videos, plus 65 additional videos for external validation. The model achieved an average sensitivity of 0.86, demonstrating high effectiveness in identifying individuals with LS. The model’s positive predictive value was 0.85, affirming its reliable LS detection, and it reached an overall accuracy rate of 0.77. External validation using an independent dataset confirmed strong generalizability with an Area Under the Curve of 0.75. Although the model accurately diagnosed LS cases, it was less precise in identifying non-LS cases. This study pioneers in diagnosing LS using computer vision technology for pose estimation. Our accessible, non-invasive model serves as a tool that can accurately diagnose the labor-intensive LS tests using only visual assessments, streamlining LS detection and expediting treatment initiation. This significantly improves patient outcomes and marks a crucial advancement in digital health, addressing key challenges in management and care of LS.
- Open Access
- 10 January 2024
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 13 (1) , 28-39
Sex differences of NF-κB-targeted therapy for mitigating osteoporosis associated with chronic inflammation of bone
Aims: Transcription factor nuclear factor kappa B (NF-κB) plays a major role in the pathogenesis of chronic inflammatory diseases in all organ systems. Despite its importance, NF-κB targeted drug therapy to mitigate chronic inflammation has had limited success in preclinical studies. We hypothesized that sex differences affect the response to NF-κB treatment during chronic inflammation in bone. This study investigated the therapeutic effects of NF-κB decoy oligodeoxynucleotides (ODN) during chronic inflammation in male and female mice.Methods: We used a murine model of chronic inflammation induced by continuous intramedullary delivery of lipopolysaccharide-contaminated polyethylene particles (cPE) using an osmotic pump. Specimens were evaluated using micro-CT and histomorphometric analyses. Sex-specific osteogenic and osteoclastic differentiation potentials were also investigated in vitro, including alkaline phosphatase, Alizarin Red, tartrate-resistant acid phosphatase staining, and gene expression using reverse transcription polymerase chain reaction (RT-PCR).Results: Local delivery of NF-κB decoy ODN in vivo increased osteogenesis in males, but not females, in the presence of chronic inflammation induced by cPE. Bone resorption activity was decreased in both sexes. In vitro osteogenic and osteoclastic differentiation assays during inflammatory conditions did not reveal differences among the groups. Receptor activator of nuclear factor kappa Β ligand (Rankl) gene expression by osteoblasts was significantly decreased only in males when treated with ODN.Conclusion: We demonstrated that NF-κB decoy ODN increased osteogenesis in male mice and decreased bone resorption activity in both sexes in preclinical models of chronic inflammation. NF-κB signalling could be a therapeutic target for chronic inflammatory diseases involving bone, especially in males.Cite this article: Bone Joint Res 2024;13(1):28–39.
- 10 January 2024
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 13 (1) , 28-39
Open AccessSex differences of NF-κB-targeted therapy for mitigating osteoporosis associated with chronic inflammation of bone
Aims: Transcription factor nuclear factor kappa B (NF-κB) plays a major role in the pathogenesis of chronic inflammatory diseases in all organ systems. Despite its importance, NF-κB targeted drug therapy to mitigate chronic inflammation has had limited success in preclinical studies. We hypothesized that sex differences affect the response to NF-κB treatment during chronic inflammation in bone. This study investigated the therapeutic effects of NF-κB decoy oligodeoxynucleotides (ODN) during chronic inflammation in male and female mice.Methods: We used a murine model of chronic inflammation induced by continuous intramedullary delivery of lipopolysaccharide-contaminated polyethylene particles (cPE) using an osmotic pump. Specimens were evaluated using micro-CT and histomorphometric analyses. Sex-specific osteogenic and osteoclastic differentiation potentials were also investigated in vitro, including alkaline phosphatase, Alizarin Red, tartrate-resistant acid phosphatase staining, and gene expression using reverse transcription polymerase chain reaction (RT-PCR).Results: Local delivery of NF-κB decoy ODN in vivo increased osteogenesis in males, but not females, in the presence of chronic inflammation induced by cPE. Bone resorption activity was decreased in both sexes. In vitro osteogenic and osteoclastic differentiation assays during inflammatory conditions did not reveal differences among the groups. Receptor activator of nuclear factor kappa Β ligand (Rankl) gene expression by osteoblasts was significantly decreased only in males when treated with ODN.Conclusion: We demonstrated that NF-κB decoy ODN increased osteogenesis in male mice and decreased bone resorption activity in both sexes in preclinical models of chronic inflammation. NF-κB signalling could be a therapeutic target for chronic inflammatory diseases involving bone, especially in males.Cite this article: Bone Joint Res 2024;13(1):28–39.
- Open Access
- 18 November 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (11) , 1665
C-C Motif Chemokine Ligand 2 Enhances Macrophage Chemotaxis, Osteogenesis, and Angiogenesis during the Inflammatory Phase of Bone Regeneration
Local cell therapy has recently gained attention for the treatment of joint diseases and fractures. Mesenchymal stem cells (MSCs) are not only involved in osteogenesis and angiogenesis, but they also have immunomodulatory functions, such as inducing macrophage migration during bone regeneration via macrophage crosstalk. C-C motif chemokine ligand 2 (CCL2), a known inflammatory mediator, is associated with the migration of macrophages during inflammation. This study examined the utility of CCL2 as a therapeutic target for local cell therapy. Using lentiviral vectors for rabbit MSCs, genetically modified CCL2 overexpressing MSCs were generated. Osteogenic differentiation assays were performed using MSCs with or without macrophages in co-culture, and cell migration assays were also performed. Additionally, co-cultures were performed with endothelial cells (ECs), and angiogenesis was evaluated using a tube formation assay. Overexpression of CCL2 did not affect bone formation under monoculture conditions but promoted chemotaxis and osteogenesis when co-cultured with macrophages. Furthermore, CCL2-overexpression promoted tube formation in co-culture with ECs. These results suggest that CCL2 induces macrophage chemotaxis and osteogenesis by promoting crosstalk between MSCs and macrophages; CCL2 also stimulates ECs to induce angiogenesis. These findings indicate that CCL2 may be a useful therapeutic target for local cell therapy in areas of bone loss.
- 18 November 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (11) , 1665
Open AccessC-C Motif Chemokine Ligand 2 Enhances Macrophage Chemotaxis, Osteogenesis, and Angiogenesis during the Inflammatory Phase of Bone Regeneration
Local cell therapy has recently gained attention for the treatment of joint diseases and fractures. Mesenchymal stem cells (MSCs) are not only involved in osteogenesis and angiogenesis, but they also have immunomodulatory functions, such as inducing macrophage migration during bone regeneration via macrophage crosstalk. C-C motif chemokine ligand 2 (CCL2), a known inflammatory mediator, is associated with the migration of macrophages during inflammation. This study examined the utility of CCL2 as a therapeutic target for local cell therapy. Using lentiviral vectors for rabbit MSCs, genetically modified CCL2 overexpressing MSCs were generated. Osteogenic differentiation assays were performed using MSCs with or without macrophages in co-culture, and cell migration assays were also performed. Additionally, co-cultures were performed with endothelial cells (ECs), and angiogenesis was evaluated using a tube formation assay. Overexpression of CCL2 did not affect bone formation under monoculture conditions but promoted chemotaxis and osteogenesis when co-cultured with macrophages. Furthermore, CCL2-overexpression promoted tube formation in co-culture with ECs. These results suggest that CCL2 induces macrophage chemotaxis and osteogenesis by promoting crosstalk between MSCs and macrophages; CCL2 also stimulates ECs to induce angiogenesis. These findings indicate that CCL2 may be a useful therapeutic target for local cell therapy in areas of bone loss.
- Top Cited PapersOpen Access
- 25 May 2023
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 43 (1) , 1-13
Bone regeneration in inflammation with aging and cell-based immunomodulatory therapy
Aging of the global population increases the incidence of osteoporosis and associated fragility fractures, significantly impacting patient quality of life and healthcare costs. The acute inflammatory reaction is essential to initiate healing after injury. However, aging is associated with “inflammaging”, referring to the presence of systemic low-level chronic inflammation. Chronic inflammation impairs the initiation of bone regeneration in elderly patients. This review examines current knowledge of the bone regeneration process and potential immunomodulatory therapies to facilitate bone healing in inflammaging.Aged macrophages show increased sensitivity and responsiveness to inflammatory signals. While M1 macrophages are activated during the acute inflammatory response, proper resolution of the inflammatory phase involves repolarizing pro-inflammatory M1 macrophages to an anti-inflammatory M2 phenotype associated with tissue regeneration. In aging, persistent chronic inflammation resulting from the failure of M1 to M2 repolarization leads to increased osteoclast activation and decreased osteoblast formation, thus increasing bone resorption and decreasing bone formation during healing.Inflammaging can impair the ability of stem cells to support bone regeneration and contributes to the decline in bone mass and strength that occurs with aging. Therefore, modulating inflammaging is a promising approach for improving bone health in the aging population. Mesenchymal stem cells (MSCs) possess immunomodulatory properties that may benefit bone regeneration in inflammation. Preconditioning MSCs with pro-inflammatory cytokines affects MSCs’ secretory profile and osteogenic ability. MSCs cultured under hypoxic conditions show increased proliferation rates and secretion of growth factors. Resolution of inflammation via local delivery of anti-inflammatory cytokines is also a potential therapy for bone regeneration in inflammaging. Scaffolds containing anti-inflammatory cytokines, unaltered MSCs, and genetically modified MSCs can also have therapeutic potential. MSC exosomes can increase the migration of MSCs to the fracture site and enhance osteogenic differentiation and angiogenesis.In conclusion, inflammaging can impair the proper initiation of bone regeneration in the elderly. Modulating inflammaging is a promising approach for improving compromised bone healing in the aging population.
- 25 May 2023
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 43 (1) , 1-13
Top Cited PapersOpen AccessBone regeneration in inflammation with aging and cell-based immunomodulatory therapy
Aging of the global population increases the incidence of osteoporosis and associated fragility fractures, significantly impacting patient quality of life and healthcare costs. The acute inflammatory reaction is essential to initiate healing after injury. However, aging is associated with “inflammaging”, referring to the presence of systemic low-level chronic inflammation. Chronic inflammation impairs the initiation of bone regeneration in elderly patients. This review examines current knowledge of the bone regeneration process and potential immunomodulatory therapies to facilitate bone healing in inflammaging.Aged macrophages show increased sensitivity and responsiveness to inflammatory signals. While M1 macrophages are activated during the acute inflammatory response, proper resolution of the inflammatory phase involves repolarizing pro-inflammatory M1 macrophages to an anti-inflammatory M2 phenotype associated with tissue regeneration. In aging, persistent chronic inflammation resulting from the failure of M1 to M2 repolarization leads to increased osteoclast activation and decreased osteoblast formation, thus increasing bone resorption and decreasing bone formation during healing.Inflammaging can impair the ability of stem cells to support bone regeneration and contributes to the decline in bone mass and strength that occurs with aging. Therefore, modulating inflammaging is a promising approach for improving bone health in the aging population. Mesenchymal stem cells (MSCs) possess immunomodulatory properties that may benefit bone regeneration in inflammation. Preconditioning MSCs with pro-inflammatory cytokines affects MSCs’ secretory profile and osteogenic ability. MSCs cultured under hypoxic conditions show increased proliferation rates and secretion of growth factors. Resolution of inflammation via local delivery of anti-inflammatory cytokines is also a potential therapy for bone regeneration in inflammaging. Scaffolds containing anti-inflammatory cytokines, unaltered MSCs, and genetically modified MSCs can also have therapeutic potential. MSC exosomes can increase the migration of MSCs to the fracture site and enhance osteogenic differentiation and angiogenesis.In conclusion, inflammaging can impair the proper initiation of bone regeneration in the elderly. Modulating inflammaging is a promising approach for improving compromised bone healing in the aging population.
- Open Access
Gait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors
Mobility impairments are a common symptom of age-related degenerative diseases. Gait features can discriminate those with mobility disorders from healthy individuals, yet phenotyping specific pathologies remains challenging. This study aims to identify if gait parameters derived from two foot-mounted inertial measurement units (IMU) during the 6 min walk test (6MWT) can phenotype mobility impairment from different pathologies (Lumbar spinal stenosis (LSS)—neurogenic diseases, and knee osteoarthritis (KOA)—structural joint disease). Bilateral foot-mounted IMU data during the 6MWT were collected from patients with LSS and KOA and matched healthy controls (N = 30, 10 for each group). Eleven gait parameters representing four domains (pace, rhythm, asymmetry, variability) were derived for each minute of the 6MWT. In the entire 6MWT, gait parameters in all four domains distinguished between controls and both disease groups; however, the disease groups demonstrated no statistical differences, with a trend toward higher stride length variability in the LSS group (p = 0.057). Additional minute-by-minute comparisons identified stride length variability as a statistically significant marker between disease groups during the middle portion of 6WMT (3rd min: p ≤ 0.05; 4th min: p = 0.06). These findings demonstrate that gait variability measures are a potential biomarker to phenotype mobility impairment from different pathologies. Increased gait variability indicates loss of gait rhythmicity, a common feature in neurologic impairment of locomotor control, thus reflecting the underlying mechanism for the gait impairment in LSS. Findings from this work also identify the middle portion of the 6MWT as a potential window to detect subtle gait differences between individuals with different origins of gait impairment.
Open AccessGait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors
Mobility impairments are a common symptom of age-related degenerative diseases. Gait features can discriminate those with mobility disorders from healthy individuals, yet phenotyping specific pathologies remains challenging. This study aims to identify if gait parameters derived from two foot-mounted inertial measurement units (IMU) during the 6 min walk test (6MWT) can phenotype mobility impairment from different pathologies (Lumbar spinal stenosis (LSS)—neurogenic diseases, and knee osteoarthritis (KOA)—structural joint disease). Bilateral foot-mounted IMU data during the 6MWT were collected from patients with LSS and KOA and matched healthy controls (N = 30, 10 for each group). Eleven gait parameters representing four domains (pace, rhythm, asymmetry, variability) were derived for each minute of the 6MWT. In the entire 6MWT, gait parameters in all four domains distinguished between controls and both disease groups; however, the disease groups demonstrated no statistical differences, with a trend toward higher stride length variability in the LSS group (p = 0.057). Additional minute-by-minute comparisons identified stride length variability as a statistically significant marker between disease groups during the middle portion of 6WMT (3rd min: p ≤ 0.05; 4th min: p = 0.06). These findings demonstrate that gait variability measures are a potential biomarker to phenotype mobility impairment from different pathologies. Increased gait variability indicates loss of gait rhythmicity, a common feature in neurologic impairment of locomotor control, thus reflecting the underlying mechanism for the gait impairment in LSS. Findings from this work also identify the middle portion of the 6MWT as a potential window to detect subtle gait differences between individuals with different origins of gait impairment.
- Open Access
- 8 September 2022
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 41 (5) , 1004-1013
Therapeutic effects of MSCs, genetically modified MSCs, and NFĸB‐inhibitor on chronic inflammatory osteolysis in aged mice
The number of total joint replacements is increasing, especially in elderly patients, and so too are implant‐related complications such as prosthesis loosening. Wear particles from the prosthesis induce a chronic inflammatory reaction and subsequent osteolysis, leading to the need for revision surgery. This study investigated the therapeutic effect of NF‐ĸB decoy oligodeoxynucleotides (ODN), mesenchymal stem cells (MSCs), and genetically‐modified NF‐ĸB sensing interleukin‐4 over‐secreting MSCs (IL4‐MSCs) on chronic inflammation in aged mice. The model was generated by continuous infusion of contaminated polyethylene particles into the intramedullary space of the distal femur of aged mice (15−17 months old) for 6 weeks. Local delivery of ODN showed increased bone mineral density (BMD), decreased osteoclast‐like cells, increased alkaline phosphatase (ALP)‐positive area, and increased M2/M1 macrophage ratio. Local injection of MSCs and IL4‐MSCs significantly decreased osteoclast‐like cells and increased the M2/M1 ratio, with a greater trend for IL4‐MSCs than MSCs. MSCs significantly increased ALP‐positive area and BMD values compared with the control. The IL4‐MSCs demonstrated higher values for both ALP‐positive area and BMD. These findings demonstrated the therapeutic effects of ODN, MSCs, and IL4‐MSCs on chronic inflammatory osteolysis in aged mice. The two MSC‐based therapies were more effective than ODN in increasing the M2/M1 macrophage ratio, reducing bone resorption, and increasing bone formation. Specifically, MSCs were more effective in increasing bone formation, and IL4‐MSCs were more effective in mitigating inflammation. This study suggests potential therapeutic strategies for treating wear particle‐associated inflammatory osteolysis after arthroplasty in the elderly.
- 8 September 2022
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 41 (5) , 1004-1013
Open AccessTherapeutic effects of MSCs, genetically modified MSCs, and NFĸB‐inhibitor on chronic inflammatory osteolysis in aged mice
The number of total joint replacements is increasing, especially in elderly patients, and so too are implant‐related complications such as prosthesis loosening. Wear particles from the prosthesis induce a chronic inflammatory reaction and subsequent osteolysis, leading to the need for revision surgery. This study investigated the therapeutic effect of NF‐ĸB decoy oligodeoxynucleotides (ODN), mesenchymal stem cells (MSCs), and genetically‐modified NF‐ĸB sensing interleukin‐4 over‐secreting MSCs (IL4‐MSCs) on chronic inflammation in aged mice. The model was generated by continuous infusion of contaminated polyethylene particles into the intramedullary space of the distal femur of aged mice (15−17 months old) for 6 weeks. Local delivery of ODN showed increased bone mineral density (BMD), decreased osteoclast‐like cells, increased alkaline phosphatase (ALP)‐positive area, and increased M2/M1 macrophage ratio. Local injection of MSCs and IL4‐MSCs significantly decreased osteoclast‐like cells and increased the M2/M1 ratio, with a greater trend for IL4‐MSCs than MSCs. MSCs significantly increased ALP‐positive area and BMD values compared with the control. The IL4‐MSCs demonstrated higher values for both ALP‐positive area and BMD. These findings demonstrated the therapeutic effects of ODN, MSCs, and IL4‐MSCs on chronic inflammatory osteolysis in aged mice. The two MSC‐based therapies were more effective than ODN in increasing the M2/M1 macrophage ratio, reducing bone resorption, and increasing bone formation. Specifically, MSCs were more effective in increasing bone formation, and IL4‐MSCs were more effective in mitigating inflammation. This study suggests potential therapeutic strategies for treating wear particle‐associated inflammatory osteolysis after arthroplasty in the elderly.
- Open Access
- 29 October 2021
- Published by MDPI AG in Bioengineering
- Vol. 8 (11) , 165
Effect on Osteogenic Differentiation of Genetically Modified IL4 or PDGF-BB Over-Expressing and IL4-PDGF-BB Co-Over-Expressing Bone Marrow-Derived Mesenchymal Stromal Cells In Vitro
The use of genetically modified (GM) mesenchymal stromal cells (MSCs) and preconditioned MSCs (pMSCs) may provide further opportunities to improve the outcome of core decompression (CD) for the treatment of early-stage osteonecrosis of the femoral head (ONFH). GM interleukin-4 (IL4) over-expressing MSCs (IL4-MSCs), platelet-derived growth factor (PDGF)-BB over-expressing MSCs (PDGF-BB-MSCs), and IL4-PDGF-BB co-over-expressing MSCs (IL4-PDGF-BB-MSCs) and their respective pMSCs were used in this in vitro study and compared with respect to cell proliferation and osteogenic differentiation. IL4-MSCs, PDGF-BB-MSCs, IL4-PDGF-BB-MSCs, and each pMSC treatment significantly increased cell proliferation compared to the MSC group alone. The percentage of Alizarin red-stained area in the IL4-MSC and IL4-pMSC groups was significantly lower than in the MSC group. However, the percentage of Alizarin red-stained area in the PDGF-BB-MSC group was significantly higher than in the MSC and PDGF-BB-pMSC groups. The percentage of Alizarin red-stained area in the IL4-PDGF-BB-pMSC was significantly higher than in the IL4-PDGF-BB-MSC group. There were no significant differences in the percentage of Alizarin red-stained area between the MSC and IL4-PDGF-BB-pMSC groups. The use of PDGF-BB-MSCs or IL4-PDGF-BB-pMSCs increased cell proliferation. Furthermore, PDGF-BB-MSCs promoted osteogenic differentiation. The addition of GM MSCs may provide a useful supplementary cell-based therapy to CD for treatment of ONFH.
- 29 October 2021
- Published by MDPI AG in Bioengineering
- Vol. 8 (11) , 165
Open AccessEffect on Osteogenic Differentiation of Genetically Modified IL4 or PDGF-BB Over-Expressing and IL4-PDGF-BB Co-Over-Expressing Bone Marrow-Derived Mesenchymal Stromal Cells In Vitro
The use of genetically modified (GM) mesenchymal stromal cells (MSCs) and preconditioned MSCs (pMSCs) may provide further opportunities to improve the outcome of core decompression (CD) for the treatment of early-stage osteonecrosis of the femoral head (ONFH). GM interleukin-4 (IL4) over-expressing MSCs (IL4-MSCs), platelet-derived growth factor (PDGF)-BB over-expressing MSCs (PDGF-BB-MSCs), and IL4-PDGF-BB co-over-expressing MSCs (IL4-PDGF-BB-MSCs) and their respective pMSCs were used in this in vitro study and compared with respect to cell proliferation and osteogenic differentiation. IL4-MSCs, PDGF-BB-MSCs, IL4-PDGF-BB-MSCs, and each pMSC treatment significantly increased cell proliferation compared to the MSC group alone. The percentage of Alizarin red-stained area in the IL4-MSC and IL4-pMSC groups was significantly lower than in the MSC group. However, the percentage of Alizarin red-stained area in the PDGF-BB-MSC group was significantly higher than in the MSC and PDGF-BB-pMSC groups. The percentage of Alizarin red-stained area in the IL4-PDGF-BB-pMSC was significantly higher than in the IL4-PDGF-BB-MSC group. There were no significant differences in the percentage of Alizarin red-stained area between the MSC and IL4-PDGF-BB-pMSC groups. The use of PDGF-BB-MSCs or IL4-PDGF-BB-pMSCs increased cell proliferation. Furthermore, PDGF-BB-MSCs promoted osteogenic differentiation. The addition of GM MSCs may provide a useful supplementary cell-based therapy to CD for treatment of ONFH.